Last reviewed · How we verify

NCT03682874: INNOVATE

Identifying Novel Aging Targets for Treatment of Delirium

Terminated Last updated 30 June 2021
What this trial tests

trial in Delirium in 5 participants. Terminated before completion.

Timeline
10 October 2018
Primary endpoint
20 February 2020
20 February 2020

Quick facts

Lead sponsorWake Forest University Health Sciences
StatusTerminated
Study typeOBSERVATIONAL
Enrollment5
Start date10 October 2018
Primary completion20 February 2020
Estimated completion20 February 2020
Sites1 location across United States

Conditions studied

Sponsor

Wake Forest University Health Sciences

Who can join

55 and older, any sex, with Delirium or Dementia Alzheimers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The long-term goal of this research program is to improve understanding of the mechanistic link between Alzheimer's disease (AD) neuropathology, acute delirium, and cognitive impairment following acute respiratory failure. In this pilot study, the study team will establish a prospective cohort of older patients with acute respiratory failure and obtain data on delirium duration, AD imaging and CSF biomarkers, and cognitive outcomes following critical illness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing